GlassScriptPhysician profile
Haley M Pope
NPI 1578685921
$6,367.33
in general payments reported to CMS, 2019-2025
36 companies · $805 in 2025
The $805 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $554 · 2021: $1,189 · 2022: $1,138 · 2023: $1,229 · 2024: $583 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Education: $26.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.12 |
| Education | $26.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,220.48 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $1,183.02 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $451.10 | 2019-2024 | Prolia, Evenity, Otezla |
| Pfizer INC. | $446.34 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.86 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $299.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $290.45 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $280.18 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Sanofi-Aventis U.S. LLC | $273.56 | 2019-2022 | |
| Exact Sciences Corporation | $196.23 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $195.65 | 2021-2024 | |
| Dexcom, INC. | $145.36 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $124.89 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $104.79 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.40 | 2021-2025 | Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bsn Medical INC | $72.37 | 2025 | |
| Janssen Pharmaceuticals, INC | $70.41 | 2019-2025 | Spravato |
| Corcept Therapeutics | $61.27 | 2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $57.94 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $54.53 | 2020-2021 | |
| Abbott Laboratories | $48.33 | 2021-2023 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $45.29 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.21 | 2019 | |
| Bausch Health US, LLC | $39.15 | 2019-2020 | |
| Organon LLC | $31.41 | 2021-2022 | |
| Allergan, INC. | $30.09 | 2019-2020 | |
| Astellas Pharma US INC | $29.37 | 2024 | Veozah |
| Indivior INC. | $21.80 | 2022 | |
| Hologic Sales and Service, LLC | $20.10 | 2023 | Aptima |
| Esperion Therapeutics, INC. | $18.98 | 2023 | Nexletol |
| Seqirus USA INC | $17.33 | 2024 | Fluad, Flucelvax |
| Sanofi Pasteur INC. | $16.99 | 2022 | |
| Orexo US, INC. | $16.91 | 2023 | Zubsolv |
| Sumitomo Pharma America, INC. | $15.58 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.